Larry Glass - Neuren Pharmaceuticals Insider

NURPF -- USA Stock  

USD 0.92  0.00  0.00%

Mr. Larry Glass was Chief Science Officer and Executive Director of Neuren Pharmaceuticals Limited since September 2, 2013. He is a seasoned manager with more than 30 years in the life sciences industry. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally, providing management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. For a number of years, the CRO operated as a subsidiary of a NYSElisted company and was subsequently sold to a European biopharmaceutical enterprise which was then acquired by Johnson Johnson.
  CEO Since 2013      
61 3 9092 0480

Management Efficiency

The company has return on total asset (ROA) of (39.89) % which means that it has lost $39.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 29.66 % meaning that it generated $29.66 on every $100 dollars invested by stockholders.

Similar Executives

Showing few of many executives

CEO Since

Jan WinkelGenmab AS
Javier RibesGrifols S A
Albert RouraGrifols S A
Peder NielsenNovozymes AS
Victor DeuGrifols S A
Geoffrey McDonoughSwedish Orphan Biovitrum AB
Albert RouraGrifols S A
Onno StolpeGalapagos NV
Howard RobinNektar Therapeutics
Victor DeuGrifols S A
Flemming OrnskovShire plc
Jose FullaGrifols S A
Jose FullaGrifols S A
Guido OelkersSwedish Orphan Biovitrum AB
Ping TseSino Biopharmaceutical Limited
Javier RibesGrifols S A

Entity Summary

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand. Neuren Pharmaceuticals is traded on OTC Market in USA.Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in PWC Tower and employs 10 people.

Neuren Pharmaceuticals Leadership Team

Joseph Horrigan, VP of Clinical Devel. and Medical Affairs
Larry Glass, CEO, Managing Director
Bruce Hancox, Independent Non-Executive Director
Jenny Harry, Non-Executive Independent Director
James Shaw, COO
Patrick Davies, Non-Executive Independent Director
Dianne Angus, Non-Executive Independent Director
Richard Treagus, Executive Chairman of the Board
Trevor Scott, Independent Non-Executive Director
Jon Pilcher, CFO, Company Secretary

Stock Performance Indicators

Did you try this?

Run Equity Search Now


Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Equity Search

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.